RDY Quote, Financials, Valuation and Earnings

Infosys Ltd. has a net margin of 13.63% compared to Dr. Reddy's Laboratories Ltd.'s net margin of 14.66%. Dr. Reddy's Laboratories Ltd.'s return on equity of 15.8% beat Infosys Ltd.'s return on equity of 29.93%.

Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.32, signalling downside risk potential of -1.15%. On the other hand Infosys Ltd. has an analysts' consensus of $19.13 which suggests that it could grow by 30.59%. Given that Infosys Ltd. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Infosys Ltd. is more attractive than Dr. Reddy's Laboratories Ltd..

Dr. Reddy's Laboratories Ltd. has a beta of 0.346, which suggesting that the stock is 65.442% less volatile than S&P 500. In comparison Infosys Ltd. has a beta of 0.989, suggesting its less volatile than the S&P 500 by 1.113%.

Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.64%. Infosys Ltd. offers a yield of 3.55% to investors and pays a quarterly dividend of $0.26 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Infosys Ltd. pays out 56.51% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr. Reddy's Laboratories Ltd. quarterly revenues are $979.5M, which are smaller than Infosys Ltd. quarterly revenues of $5.1B. Dr. Reddy's Laboratories Ltd.'s net income of $133.5M is lower than Infosys Ltd.'s net income of $748.2M. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 18.59x while Infosys Ltd.'s PE ratio is 18.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 3.05x versus 3.06x for Infosys Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk A/S has a net margin of 13.63% compared to Dr. Reddy's Laboratories Ltd.'s net margin of 33.98%. Dr. Reddy's Laboratories Ltd.'s return on equity of 15.8% beat Novo Nordisk A/S's return on equity of 62.44%.

Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.32, signalling downside risk potential of -1.15%. On the other hand Novo Nordisk A/S has an analysts' consensus of $53.78 which suggests that it could grow by 13.4%. Given that Novo Nordisk A/S has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Novo Nordisk A/S is more attractive than Dr. Reddy's Laboratories Ltd..

Dr. Reddy's Laboratories Ltd. has a beta of 0.346, which suggesting that the stock is 65.442% less volatile than S&P 500. In comparison Novo Nordisk A/S has a beta of 0.667, suggesting its less volatile than the S&P 500 by 33.292%.

Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.64%. Novo Nordisk A/S offers a yield of 3.64% to investors and pays a quarterly dividend of $0.58 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Novo Nordisk A/S pays out 38.07% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr. Reddy's Laboratories Ltd. quarterly revenues are $979.5M, which are smaller than Novo Nordisk A/S quarterly revenues of $12.3B. Dr. Reddy's Laboratories Ltd.'s net income of $133.5M is lower than Novo Nordisk A/S's net income of $4.2B. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 18.59x while Novo Nordisk A/S's PE ratio is 13.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 3.05x versus 4.52x for Novo Nordisk A/S. Usually stocks with elevated PS ratios are considered overvalued.

111, Inc. has a net margin of 13.63% compared to Dr. Reddy's Laboratories Ltd.'s net margin of -0.5%. Dr. Reddy's Laboratories Ltd.'s return on equity of 15.8% beat 111, Inc.'s return on equity of -26.11%.

Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.32, signalling downside risk potential of -1.15%. On the other hand 111, Inc. has an analysts' consensus of -- which suggests that it could grow by 634%. Given that 111, Inc. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe 111, Inc. is more attractive than Dr. Reddy's Laboratories Ltd..

Dr. Reddy's Laboratories Ltd. has a beta of 0.346, which suggesting that the stock is 65.442% less volatile than S&P 500. In comparison 111, Inc. has a beta of 0.674, suggesting its less volatile than the S&P 500 by 32.648%.

Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.64%. 111, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. 111, Inc. pays out -- of its earnings as a dividend. Dr. Reddy's Laboratories Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr. Reddy's Laboratories Ltd. quarterly revenues are $979.5M, which are larger than 111, Inc. quarterly revenues of $419.3M. Dr. Reddy's Laboratories Ltd.'s net income of $133.5M is higher than 111, Inc.'s net income of -$2.1M. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 18.59x while 111, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 3.05x versus 0.04x for 111, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab Ltd. has a net margin of 13.63% compared to Dr. Reddy's Laboratories Ltd.'s net margin of -30.98%. Dr. Reddy's Laboratories Ltd.'s return on equity of 15.8% beat Zai Lab Ltd.'s return on equity of -26.7%.

Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.32, signalling downside risk potential of -1.15%. On the other hand Zai Lab Ltd. has an analysts' consensus of $43.42 which suggests that it could grow by 116.67%. Given that Zai Lab Ltd. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Zai Lab Ltd. is more attractive than Dr. Reddy's Laboratories Ltd..

Dr. Reddy's Laboratories Ltd. has a beta of 0.346, which suggesting that the stock is 65.442% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.879, suggesting its less volatile than the S&P 500 by 12.141%.

Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.64%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend. Dr. Reddy's Laboratories Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr. Reddy's Laboratories Ltd. quarterly revenues are $979.5M, which are larger than Zai Lab Ltd. quarterly revenues of $116.2M. Dr. Reddy's Laboratories Ltd.'s net income of $133.5M is higher than Zai Lab Ltd.'s net income of -$36M. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 18.59x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 3.05x versus 4.87x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.